Indian biopharmaceutical company MannKind has agreed to sign a marketing and distribution agreement with Cipla for the inhaled insulin drug, Afrezza.
MannKind will supply the FDA-approved drug to Cipla for distribution and marketing in India as part of the agreement.
Go deeper with GlobalData
Cipla will make an upfront payment of $2.2m to MannKind within one month of signing the agreement. It will also make additional regulatory milestone payments, as well as royalties from sales of Afrezza India to MannKind.
US-based computation-driven pharmaceutical technology company XtalPi has signed a research collaboration agreement with Pfizer.
The two companies will collaborate to develop hybrid physics and an artificial intelligence (AI)-powered software platform, which will be helpful to find accurate molecular modelling of drug-like small molecules.
The collaboration builds on the existing association between the two companies on crystal structure prediction (CSP).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAscendia Pharmaceuticals has agreed to collaborate with KC Pharmaceuticals for the development of five over-the-counter (OTC) sterile ophthalmic drop medicines.
Based in the US, Ascendia Pharmaceuticals develops formulations of existing drugs and facilitates formulations for pre-clinical and clinical stage products, while KC Pharmaceuticals, also based in the US, is a producer and distributor of private-label over-the-counter eye care, contact lens care, anti-diarrhoea, and nasal spray products.
Lannett Company has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International.
The product portfolio includes oral solutions with a few semi-solid products.
Lannett will pay an upfront payment and future milestone payments to the subsidiary as part of the agreement.
Based in the US, Lannett Company is a developer, manufacturer, packager and distributor of generic pharmaceutical products, while Endo International is a generics and specialist branded pharmaceutical company.
The acquisition will enable Lannett to diversify its product offering.
Endo International has appointed Bourne Partners as the lead financial adviser for the transaction.
